12.57

0.40% 0.05

After Hours: 12.57

Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is traded at $12.57, with a volume of 370.38K. It is up +0.40% in the last 24 hours and down -1.80% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Previous Close:

$12.52

Open:

$12.41

24h Volume:

370.38K

Relative Volume:

0.62

Market Cap:

$817.53M

Revenue:

$62.71M

Net Income/Loss:

$-112.51M

P/E Ratio:

-8.3245

EPS:

-1.51

Net Cash Flow:

$-96.01M

1W Performance:

+9.02%

1M Performance:

-1.80%

6M Performance:

-2.78%

1Y Performance:

+54.99%

1-Day Range:

$12.23

$12.58

1-Week Range:

$11.34

$12.93

52-Week Range:

$7.97

$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Name

Zymeworks Inc.

Sector

Healthcare (1154)

Industry

Biotechnology (677)

Phone

604-678-1388

Address

1385 West 8th Avenue, Suite 540, Vancouver, BC

Employee

170

Twitter

@ZymeworksInc

Next Earnings Date

2024-10-31

Latest SEC Filings

ZYME's Discussions on Twitter

Compare ZYME with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZYME Zymeworks Inc.	12.57	817.53M	62.71M	-112.51M	-96.01M	-1.51
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-21-23	Resumed	Wells Fargo	Overweight
Jan-04-23	Reiterated	H.C. Wainwright	Neutral
Dec-20-22	Upgrade	Jefferies	Hold → Buy
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-04-22	Resumed	Wells Fargo	Overweight
May-05-22	Upgrade	Guggenheim	Neutral → Buy
Mar-15-22	Initiated	Evercore ISI	Outperform
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-08-21	Resumed	H.C. Wainwright	Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-06-20	Initiated	SVB Leerink	Outperform
Jan-10-20	Initiated	Wolfe Research	Outperform
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy
Nov-20-19	Initiated	Guggenheim	Buy
Sep-30-19	Upgrade	Raymond James	Outperform → Strong Buy
Aug-30-19	Initiated	Stifel	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
May-11-18	Upgrade	Barclays	Underweight → Equal Weight
Mar-19-18	Initiated	Raymond James	Outperform

View All

Zymeworks Inc. Stock (ZYME) Latest News

Apr 25, 2025

Zymeworks Presents New Data from Multiple Development Programs a - GuruFocus

Apr 25, 2025

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting - GlobeNewswire

Apr 25, 2025

Zymeworks Unveils Breakthrough Cancer Drug Data: T-Cell Engagers Show Strong Activity in Lung, Ovarian Cancers - Stock Titan

Apr 25, 2025

Apr 21, 2025

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development - The Financial World

Apr 21, 2025

Zymeworks appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development - MediaNews4U

Apr 21, 2025

Zymeworks Strengthens Clinical Leadership with New Senior VP Appointment - TipRanks

Apr 21, 2025

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development | ZYME Stock News - GuruFocus

Apr 21, 2025

Zymeworks Strengthens Cancer Drug Pipeline: Top Oncology Expert Takes Helm of Clinical Development - Stock Titan

Apr 21, 2025

Apr 18, 2025

Major Investment Alert: Ecor1 Capital Boosts Stake in Zymeworks! - TipRanks

Apr 18, 2025

Apr 17, 2025

Zymeworks to Announce Q1 2025 Financial Results and Host Conference Call - TipRanks

Apr 17, 2025

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 | ZYME Stock News - GuruFocus

Apr 17, 2025

Zymeworks Inc. to Announce First Quarter 2025 Financial Results on May 8, 2025 - Nasdaq

Apr 17, 2025

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire

Apr 17, 2025

Apr 09, 2025